Loading company
Scholar Rock Holding Corporation
SRRK · Nasdaq · ·
$43.16-0.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
Past performance
- 1W
- -8.1%
- 1M
- +6.2%
Scholar Rock Holding Corporation against biotechnology
Scholar Rock Holding Corporation is the 46th largest of 352 graded companies. Showing 5 of them, including SRRK itself. 245 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc.CRNX | D- | — | $42.2M | -1,189.9% | -$425.2M | — |
| OSR Health, Inc.OSRH | D- | — | $1.7M | -781.5% | — | — |
| Lunai Bioworks Inc.LNAI | B | — | $52K | -6,852.0% | -$5.3M | — |
| Barinthus Biotherapeutics plcBRNS | D- | — | $0.00 | — | -$26.4M | — |
| Scholar Rock Holding CorporationSRRK | F- | $5.3B | $570K | -72,563.2% | -$309.9M | — |
347 more biotechnology companies
Graded on the same five checks, from their own SEC filings.
How it compares with its industry
Three ratings, each a percentile against the 582 companies we cover in Biotechnology. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.
Momentum
74of 100 in its industry
Above most of its industry
12 months to a month ago18.2%
6 months to a month ago-18.2%
The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.
Value
39of 100 in its industry
Below most of its industry
Profit for the price-7.85%
Cash for the price-5.89%
Sales for the price0.01%
Assets for the price4.66%
Operating profit for the whole business—
Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. Blended from 4 of 5 measures.
Capital allocation
0/2
4 checks not reported
Return on capital-85.7%
Shareholder yield—
Share count, 3 years104.7%
Net debt / EBITDA—
Insiders, 12 months-$15.4M
What management does with the money — scored on whatever the filings answer, never as a share of the total.
The six capital-allocation checks
- Return on the money invested-85.7% on invested capital
- Debt against earningsNo comparable earnings to measure debt against
- Cash returned to shareholdersNeither buybacks nor dividends reported
- Share count over three yearsShare count 104.7% higher over three years
- Payouts covered by cash flowNot enough reported to compare
- Open-market insider buyingNet selling of $15.4M — not counted against the score
A description of where this company sits among its competitors, not a recommendation. Ratings updated Nov 14, 2026.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Scholar Rock Holding Corporation on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.